代謝機能障害関連脂肪肝疾患（MASLD）患者を対象としたLY3849891の単回漸増および反復投与試験

基本情報

NCT ID: NCT05395481
ステータス: 実施中（募集終了）
試験のフェーズ: 第1相
試験タイプ: 介入
目標被験者数: 176
治験依頼者名: Eli Lilly and Company

概要

The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts A and B.

対象疾患

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

介入

LY3849891(DRUG)

Placebo(DRUG)

依頼者（Sponsor）

日本イーライリリー株式会社(INDUSTRY)

実施施設 (2)

一般社団法人　ＩＣＲ　附属　クリニカルリサーチ東京病院

Shinjuku-ku, Japan

P-One Clinic

Hachiōji, Japan